The Top 5 Biosimilars Articles for the Week of December 30

The Center for Biosimilars® recaps the top stories for the week of December 30, 2019.


Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of December 30, 2019.

Number 5: A recent study concluded that, for patients who experienced side effects or a loss of response after switching to biosimilar infliximab, a switch back to the reference product was effective.

Number 4: Anti—tumor necrosis factor therapies could play a role in alleviating or even preventing some adverse events related to immune checkpoint inhibition.

Number 3: Recent research shows that many US patients with rheumatoid arthritis who do not respond well to conventional drugs are not advancing to biologic treatment.

Number 2: Clover Biopharmaceuticals announced this week that it has dosed the first patient in a phase 3 clinical study of a proposed etanercept biosimilar.

Number 1: An official working group of the Swiss Society of Gastroenterology has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease.

To read all of these articles and more, visit